Inactive Instrument

All News Priveterra Acquisition Corp. II Nasdaq

Equities

PMGMU

US8765452037

All News

Unlock all the news: Be the first to know and act before the market!

AEON Biopharma Reports First Quarter 2024 Financial Results	15/05	AQ
AEON Biopharma Provides Update on Development Pipeline	09/05	AQ
Priveterra Acquisition Corp. II(NasdaqCM:PMGM) dropped from NASDAQ Composite Index	09/05	CI
Priveterra Acquisition Corp. II Announces Receipt of Notice from Nasdaq Regarding Late Filing of Annual Report on Form 10-K	04/05	BU
AEON Biopharma Announces Preliminary Top-Line Results from Phase 2 Interim Analysis of ABP-450 in the Preventive Treatment of Chronic Migraine	03/05	AQ
AEON Biopharma Announces Redemption of Public Warrants - March 29, 2024	01/04	AQ
CORRECTION -- AEON Biopharma Announces Redemption of Public Warrants	31/03	AQ
AEON Biopharma Announces Redemption of Public Warrants	30/03	AQ
AEON Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results	30/03	AQ
AEON Biopharma Announces Clinical Update and Productive End-of-Phase 2 Meeting with FDA on ABP-450 (prabotulinumtoxinA) for the Preventive Treatment of Migraine	20/03	AQ
AEON Biopharma Announces $15 Million Financing Transaction and Termination of Forward Purchase Agreements	20/03	AQ
AEON Biopharma Presents Positive Clinical and Pre-clinical Data for ABP-450 (prabotulinumtoxinA) in Treating Cervical Dystonia and PTSD, Respectively, at a Leading Neurotoxin Conference	19/01	AQ
AEON Biopharma Completes Enrollment in Phase 2 Study of ABP-450 (prabotulinumtoxinA) for Preventive Treatment of Chronic Migraine	12/12	AQ
Priveterra Acquisition Corp. II Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	20/11	CI
AEON Biopharma Reports Third Quarter 2023 Financial Results	13/11	AQ
AEON Biopharma Announces Topline Results from Phase 2 Trial of ABP-450 (prabotulinumtoxinA) for the Preventive Treatment of Episodic Migraine	20/23/20	AQ
AEON Biopharma Presents Positive Results from Phase 2 Clinical Trial of ABP-450 (prabotulinumtoxinA) in Cervical Dystonia at the International Parkinson and Movement Disorders Society Congress®	29/23/29	AQ
AEON Biopharma Receives Notice of Allowance from USPTO for a Patent Covering Use of Botulinum Toxins to Treat Migraine Headache	24/23/24	AQ
Priveterra Acquisition Corp. II Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	22/23/22	CI
Tastemaker Acquisition Corp. has Changed its Name to Priveterra Acquisition Corp. II	17/23/17	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

All News Priveterra Acquisition Corp. II Nasdaq

Equities

PMGMU

US8765452037

All News

Filters